/
PRME
$3.72+$0.29 (+8.45%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$619.5M
181M shares
52-week range
$2.28 – $6.94
31% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.35%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-11.65
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $5.2M | $0 | $0 | $0 | $3.0M | $4.6M |
| Cost of revenue | $2.8M | $3.0M | $0 | $0 | $0 | $0 | $7.3M |
| Gross profit | −$2.8M | $2.2M | $0 | $0 | $0 | $3.0M | −$2.7M |
| Gross margin | — | 42.8% | — | — | — | 100.0% | -58.1% |
| R&D | $920.0K | $3.0M | $70.5M | $86.7M | $147.9M | $155.3M | $160.6M |
| Operating income | −$2.2M | −$932.0K | −$84.5M | −$116.5M | −$204.8M | −$202.5M | −$208.3M |
| EBITDA | −$2.2M | −$889.0K | −$165.3M | −$120.5M | −$186.6M | −$189.8M | −$195.8M |
| Net income | −$2.5M | −$3.4M | −$165.4M | −$121.8M | −$198.1M | −$195.9M | −$201.1M |
| Net margin | — | -65.5% | — | — | — | -6566.6% | -4342.4% |
| EPS (diluted) | -0.03 | -0.05 | -1.92 | -1.46 | -2.18 | -1.65 | -1.35 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-1.00 | $-1.20–$-0.91 | 10 |
| 2027 | $23M | $-0.91 | $-1.16–$-0.69 | 7 |
| 2028 | $31M | $-0.81 | $-1.10–$-0.55 | 7 |
| 2029 | $18M | $-0.93 | $-4.11–$0.13 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Prime Medicine, Inc. Common Stock
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
www.primemedicine.com- Employees
- 146
- IPO / List date
- Oct 20, 2022
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds PRME.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 741,039 | $2.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PRME yet.
